Gadolinium is a liquid, man-made heavy-metal substance used in MRI and MRA scans. It is part of a gadolinium-based contrast agent (GBCA), which is used to make images in MRI scans clearer. Gadolinium-based contrast agents are given via an intravenous injection that generally takes between 10 and 30 seconds.
UK's Medicines and Healthcare products Regulatory Agency has announced that it will remove two gadolinium-based contrast agents (GBCAs) from the market in the wake of a review that found some patients are at risk of retaining the heavy-metal. The announcement was made on December 14, 2017, and will take effect February 1, 2018. Meanwhile, other gadolinium contrast agents will have their use limited.
How does industry funding impact patients?